A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Mayo Clinic
Baylor College of Medicine
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Seagen Inc.
Medical College of Wisconsin
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Washington University School of Medicine
Ohio State University Comprehensive Cancer Center
Boehringer Ingelheim
Ruijin Hospital
City of Hope Medical Center
Wake Forest University Health Sciences
Stanford University
Children's Oncology Group
University of Nebraska
Tessa Therapeutics
Pfizer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Barbara Ann Karmanos Cancer Institute
Children's Hospital Medical Center, Cincinnati
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Novartis
Barbara Ann Karmanos Cancer Institute
University of Wisconsin, Madison
University of Wisconsin, Madison
Mayo Clinic
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Takeda
Swiss Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
Virginia Commonwealth University
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Immune Cell, Inc.
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
University of California, San Francisco
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)